OverviewSuggest Edit

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
TypePublic
Founded2006
HQNew York, NY, US
Websiteanavex.com

Latest Updates

Employees (est.) (Sept 2019)16(+24%)
Share Price (Sept 2021)$19.3(+10%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Anavex

Christopher U. Missling

Christopher U. Missling

CEO
Tom Skarpelos

Tom Skarpelos

Director
Tasos Zografidis

Tasos Zografidis

Vice President Clinical Operations
Ulrich Elben

Ulrich Elben

Vice President of Preclinical Operations
Show more

Anavex Office Locations

Anavex has offices in New York and Reno
New York, NY, US (HQ)
51 W 52nd St
Reno, NV, US
50 W. Liberty, 50 W Liberty St #880
Show all (2)

Anavex Financials and Metrics

Anavex Revenue

USD

Net income (Q2, 2021)

(8.2m)

Market capitalization (23-Sept-2021)

1.3b

Closing stock price (23-Sept-2021)

19.3

Cash (31-Mar-2021)

75.9m
Anavex's current market capitalization is $1.3 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Sales and marketing expense

133.8k

General and administrative expense

30.1k9.1k4.0k2.2m4.8m8.3m5.0m6.0m6.8m

R&D expense

2.6m2.7m263.8k732.4k2.3m7.3m10.7m13.3m22.3m

Operating expense total

2.8m2.7m267.9k3.0m7.1m15.6m15.7m19.3m29.1m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Sales and marketing expense

38.7k15.0k7.6k

General and administrative expense

5.0k3.2k2.3k3.0k112.0295.02.3k903.0k733.8k452.1k451.2k713.5k3.9m852.8k1.4m1.1m1.1m1.4m1.5m1.6m1.8m2.1m1.4m1.4m1.7m1.4m1.5m2.2m

R&D expense

778.0k1.7m429.6k394.0k127.0k560.039.0k5.2k118.2k265.0k318.6k407.1k799.5k670.7k1.3m917.3k2.0m2.5m2.3m3.2m3.0m5.7m6.1m5.8m6.3m6.1m6.7m7.9m6.7m

Operating expense total

821.6k1.7m439.5k396.9k127.0k672.039.3k7.5k1.0m998.8k770.7k858.3k1.5m4.5m2.2m2.3m3.2m3.6m3.7m4.7m4.6m7.5m8.1m7.1m7.7m7.8m8.1m9.4m9.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

134.7k11.4k345.1k7.3m15.3m9.2m27.4m22.9m22.2m

Prepaid Expenses

9.6k48.4k89.1k100.8k335.9k1.3m501.0k

Current Assets

200.6k12.6k393.4k7.4m15.5m27.8m24.3m25.3m

PP&E

2.4k576.02.2k1.3k
USDQ3, 2011

Financial Leverage

-1.3 x
Show all financial metrics

Anavex Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Anavex Online and Social Media Presence

Embed Graph

Anavex News and Updates

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s diseas…

Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s diseas…

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

Published in Scientific Reports, Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome

Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021

Webcast and Conference Call To be Held Thursday, August 12, 2021, 4:30 pm EDT Webcast and Conference Call To be Held Thursday, August 12, 2021, 4:30 pm EDT

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease…

Thinking about buying stock in LendingClub, Nokia, Anavex Life Sciences, Flora Growth Corp, or DiDi Global?

NEW YORK, July 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LC, NOK, AVXL, FLGC, and DIDI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Anavex Blogs

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Exceeding of Enrollment Target …

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering NEW YORK – June 24, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative …

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease  NEW YORK – June 14, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinic…

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook  Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – May 13, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing d…

Anavex Life Sciences Announces Participation at Upcoming World EPA – Evidence, Pricing and Access – Congress 2021

Anavex Life Sciences Announces Participation at Upcoming World EPA – Evidence, Pricing and Access – Congress 2021   NEW YORK – April 7, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for …

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit – West Coast

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit – West Coast NEW YORK – February 19, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the tre…
Show more

Anavex Frequently Asked Questions

  • When was Anavex founded?

    Anavex was founded in 2006.

  • Who are Anavex key executives?

    Anavex's key executives are Christopher U. Missling, Tom Skarpelos and Tasos Zografidis.

  • How many employees does Anavex have?

    Anavex has 16 employees.

  • Who are Anavex competitors?

    Competitors of Anavex include Iterion Therapeutics, Memgen and Cassava Sciences.

  • Where is Anavex headquarters?

    Anavex headquarters is located at 51 W 52nd St, New York.

  • Where are Anavex offices?

    Anavex has offices in New York and Reno.

  • How many offices does Anavex have?

    Anavex has 2 offices.